Lauren McGinty1, Jill Kolesar2,3. 1. University of Wisconsin Health, Madison, WI. 2. College of Pharmacy, University of Kentucky, Lexington, KY jill.kolesar@uky.edu. 3. Early Phase Clinical Trials Center, Markey Cancer Center, Lexington, KY. jill.kolesar@uky.edu.
Abstract
PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed. SUMMARY: Dinutuximab (Unituxin, United Therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma. Its approval has led to the first major change in standard recommended first-line maintenance therapy for high-risk pediatric neuroblastoma in over a decade. Dinutuximab causes antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity by binding to GD2, a tumor-associated antigen. The recommended dosage of dinutuximab is 17.5 mg/m2/day for 4 consecutive days of each 24- or 32-day cycle, for a maximum of 5 cycles. In a Phase III trial, patients who received dinutuximab as part of combination immunotherapy in addition to standard maintenance therapy had significantly improved 2-year event-free survival relative to those who received standard maintenance therapy alone (66% versus 46%, p < 0.01). Dinutuximab has a unique adverse-effect profile that includes infusion reactions, neuropathic pain, and electrolyte abnormalities; the most common adverse effects observed with dinutuximab use in clinical trials were pain, pyrexia, myelosuppression, infusion reactions, and electrolyte abnormalities. CONCLUSION: Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.
PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed. SUMMARY:Dinutuximab (Unituxin, United Therapeutics) is a novel monoclonal antibody recently approved for use in combination with granulocyte- macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma. Its approval has led to the first major change in standard recommended first-line maintenance therapy for high-risk pediatric neuroblastoma in over a decade. Dinutuximab causes antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity by binding to GD2, a tumor-associated antigen. The recommended dosage of dinutuximab is 17.5 mg/m2/day for 4 consecutive days of each 24- or 32-day cycle, for a maximum of 5 cycles. In a Phase III trial, patients who received dinutuximab as part of combination immunotherapy in addition to standard maintenance therapy had significantly improved 2-year event-free survival relative to those who received standard maintenance therapy alone (66% versus 46%, p < 0.01). Dinutuximab has a unique adverse-effect profile that includes infusion reactions, neuropathic pain, and electrolyte abnormalities; the most common adverse effects observed with dinutuximab use in clinical trials were pain, pyrexia, myelosuppression, infusion reactions, and electrolyte abnormalities. CONCLUSION:Dinutuximab is a novel monoclonal antibody that is efficacious as part of combination immunotherapy in pediatric patients with high-risk neuroblastoma.
Authors: Irina V Kholodenko; Daniel V Kalinovsky; Igor I Doronin; Sergey M Deyev; Roman V Kholodenko Journal: J Immunol Res Date: 2018-07-11 Impact factor: 4.818
Authors: Mohsin El Amrani; Celina L Szanto; C Erik Hack; Alwin D R Huitema; Stefan Nierkens; Erik M van Maarseveen Journal: Anal Bioanal Chem Date: 2018-06-25 Impact factor: 4.142
Authors: Paula Martinez Sanz; Dieke J van Rees; Hanke L Matlung; Godelieve A M Tytgat; Katka Franke; Lieke M J van Zogchel; Bart Klein; Panagiota Bouti; Hugo Olsman; Karin Schornagel; Ivana Kok; Ali Sunak; Kira Leeuwenburg; Ilse Timmerman; Miranda P Dierselhuis; Waleed M Kholosy; Jan J Molenaar; Robin van Bruggen; Timo K van den Berg; Taco W Kuijpers Journal: J Immunother Cancer Date: 2021-05 Impact factor: 13.751